摘要
目的 比较氨磺必利与利培酮治疗首发精神分裂症的临床疗效及其对社会功能的影响.方法采用随机数字表法将符合《国际疾病分类（第10版）》（ICD-10）精神分裂症诊断标准的精神分裂症患者70例分为氨磺必利组（观察组）和利培酮组（对照组）各35例,观察组采用氨磺必利治疗,对照组采用利培酮治疗.采用阳性和阴性症状量表（PANSS）评定两组临床疗效,应用住院精神病人社会功能评定量表（SSPI）评定社会功能.结果 治疗8周后,观察组PANSS中阴性症状因子得分为（15.04±3.55）分,较对照组的（17.82±3.87）分显著改善,差异有统计学意义（t=3.132,P〈0.05）;观察组SSPI中动性和交往情况、社会性活动技能因子分及总分分别为（15.49±3.54）分、（14.53±4.25）分、（39.25±8.27）分,对照组分别为（12.78±3.29）分、（10.01±3.78）分、（33.72±7.83）分,两组差异均有统计学意义（t=3.317、4.701、2.873,均P〈0.05）.结论 氨磺必利对改善精神分裂症患者的阴性症状、社会功能优于利培酮.
Objective To explore the effect of amisulpride and risperidone in the treatment of patients with first-episode schizophrenia and its influence on social function.Methods 70 patients of schizophrenia conformed to the International classification of diseases tenth edition（ICD-10） were randomly divided into amisulpride group（observation group,35 cases） and risperidone group（control group,35 cases） by using the random number table method.The Positive and Negative Scale（PANSS） was used to evaluate the efficacy,the Scale of Social Function in Psychosis Inpatients（SSPI） was used to evaluate social function before and after 8 weeks of treatment.Results After 8 weeks treatment,the negative symptom factor score of the PANSS in the observation group was （15.04±3.55）points,which was improved significantly compared with （17.82±3.87）points in the control group,the difference was statistically significant（t=3.132,P〈0.05）.The scores of the field in movement and interaction,social activities and skills factor score and the total score of SSPI in the observation group were （15.49±3.54）points,（14.53±4.25）points,（39.25±8.27）points,respectively,which in the control group were （12.78±3.29）points,（10.01±3.78）points,（33.72±7.83）points,respectively,the differences between the two groups were statistically significant （t=3.317,4.701,2.873,all P〈0.05）.Conclusion Amisulpride is effective in improving the negative symptoms,social function in patients with schizophrenia,and the effect is better than risperidone.
出处
《中国基层医药》
CAS
2017年第14期2199-2202,共4页
Chinese Journal of Primary Medicine and Pharmacy
